Search

Your search keyword '"Recher, Christian"' showing total 19 results
Start Over Author "Recher, Christian" Publisher wiley
19 results on '"Recher, Christian"'

2. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia

Author

Jonas, Brian A., primary, Wei, Andrew H., additional, Recher, Christian, additional, DiNardo, Courtney D., additional, Jang, Jun‐Ho, additional, Pratz, Keith, additional, Panayiotidis, Panayiotis, additional, Montesinos, Pau, additional, Yeh, Su‐Peng, additional, Ivanov, Vladimir, additional, Fiedler, Walter, additional, Yamauchi, Takahiro, additional, Duan, Yinghui, additional, Mendes, Wellington, additional, Potluri, Jalaja, additional, Tews, Björn, additional, and Ofran, Yishai, additional

Published
2022
Full Text
View/download PDF

3. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations

Author

Adès, Lionel, primary, Duployez, Nicolas, additional, Guerci‐Bresler, Agnes, additional, Laribi, Kamel, additional, Peterlin, Pierre, additional, Vey, Norbert, additional, Thepot, Sylvain, additional, Wickenhauser, Stefan, additional, Zerazhi, Hacene, additional, Stamatoullas, Aspassia, additional, Wattel, Eric, additional, Recher, Christian, additional, Toma, Andrea, additional, Dimicoli‐Salazar, Sophie, additional, Braun, Thorsten, additional, Beyne‐Rauzy, Odile, additional, Marolleau, Jean‐Pierre, additional, Cheze, Stéphane, additional, Park, Sophie, additional, Cluzeau, Thomas, additional, Nimubona, Stanislas, additional, Bordessoule, Dominique, additional, Benramdane, Riad, additional, Quesnel, Bruno, additional, Amé, Shanti, additional, de Botton, Stéphane, additional, Chermat, Fathia, additional, Preudhomme, Claude, additional, Chevret, Sylvie, additional, and Fenaux, Pierre, additional

Published
2022
Full Text
View/download PDF

4. Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis

Author

de Botton, Stéphane, primary, Brandwein, Joseph M., additional, Wei, Andrew H., additional, Pigneux, Arnaud, additional, Quesnel, Bruno, additional, Thomas, Xavier, additional, Legrand, Ollivier, additional, Recher, Christian, additional, Chantepie, Sylvain, additional, Hunault‐Berger, Mathilde, additional, Boissel, Nicolas, additional, Nehme, Salem A., additional, Frattini, Mark G., additional, Tosolini, Alessandra, additional, Marion‐Gallois, Roland, additional, Wang, Jixian J., additional, Cameron, Chris, additional, Siddiqui, Muhaimen, additional, Hutton, Brian, additional, Milkovich, Gary, additional, and Stein, Eytan M., additional

Published
2021
Full Text
View/download PDF

5. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐19

Author

Maquet, Julien, Lafaurie, Margaux, Sommet, Agnès, Moulis, Guillaume, Alvarez, Muriel, Amar, Jacques, Attal, Michel, Balardy, Laurent, Balen, Frédéric, Beyne‐Rauzy, Odile, Bouali, Ourdia, Bounes, Fanny, Bureau, Christophe, Buscail, Louis, Calviere, Lionel, Charpentier, Sandrine, Chollet, François, Claudet, Isabelle, Constantin, Arnaud, Debard, Alexa, Delavigne, Karen, Delobel, Pierre, Delrieu, Julien, Didier, Alain, Faruch, Marie, Fourcade, Olivier, Georges, Bernard, Grunenwald, Etienne, Guyonnet, Sophie, Hanaire, Hélène, Hein, Christophe, Kamar, Nassim, Lairez, Olivier, Mansat, Pierre, Martin‐Blondel, Guillaume, Minville, Vincent, Pariente, Jérémie, Paul, Carle, Payoux, Pierre, Pugnet, Grégory, Piel‐Julian, Marie‐Léa, Recher, Christian, Rolland, Yves, Ruyssen‐Witrand, Adeline, Sabatier, Jean, Sailler, Laurent, Salles, Jean‐Pierre, Sans, Nicolas, Secher, Marion, Sevely, Annick, Silva, Stein, Thalamas, Claire, and Toulza, Olivier

Subjects
Male, medicine.medical_specialty, Letter, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Population, thrombocytopenia, COVID‐2019, intensive care unit, SARS‐CoV‐2, Disease-Free Survival, law.invention, Betacoronavirus, 03 medical and health sciences, 0302 clinical medicine, law, Internal medicine, medicine, Humans, Platelet, Letters, Prospective Studies, Platelet activation, education, Prospective cohort study, Pandemics, Survival rate, Aged, education.field_of_study, Hematology, SARS-CoV-2, business.industry, COVID-19, Middle Aged, mortality, Intensive care unit, Hospitalization, Survival Rate, 030220 oncology & carcinogenesis, Female, Coronavirus Infections, business, 030215 immunology
Abstract

Thrombocytopenia (defined by platelet count

Published
2020
Full Text
View/download PDF

6. A case of cup‐like blasts associated with B‐lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations

Author

Rieu, Jean‐Baptiste, primary, Coster, Lucie, additional, Corre, Jill, additional, Tavitian, Suzanne, additional, Recher, Christian, additional, Huynh, Anne, additional, Picard, Muriel, additional, Derreumaux, Celine, additional, Bertoli, Sarah, additional, Vergez, Francois, additional, and Largeaud, Laetitia, additional

Published
2020
Full Text
View/download PDF

7. Impact of body-surface area on patients’ outcome in younger adults with acute myeloid leukemia

Author

Cahu, Xavier, primary, Carré, Martin, additional, Recher, Christian, additional, Pigneux, Arnaud, additional, Hunault-Berger, Mathilde, additional, Vey, Norbert, additional, Chevallier, Patrice, additional, Delaunay, Jacques, additional, Gyan, Emmanuel, additional, Lioure, Bruno, additional, Bonmati, Caroline, additional, Himberlin, Chantal, additional, Hicheri, Yosr, additional, Guillerm, Gaelle, additional, Didier, Bouscary, additional, Larosa, Fabrice, additional, Ojeda-Uribe, Mario, additional, Bernard, Marc, additional, Bene, Marie C., additional, Ifrah, Norbert, additional, and Cahn, Jean-Yves, additional

Published
2017
Full Text
View/download PDF

9. Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities

Author

Wanquet, Anne, primary, Prebet, Thomas, additional, Berthon, Céline, additional, Sebert, Marie, additional, Roux, Clémence, additional, Kulasekararaj, Austin, additional, Micol, Jean-Baptiste, additional, Esterni, Benjamin, additional, Itzykson, Raphael, additional, Thepot, Sylvain, additional, Recher, Christian, additional, Delaunay, Jacques, additional, Dreyfus, François, additional, Mufti, Ghulam, additional, Fenaux, Pierre, additional, and Vey, Norbert, additional

Published
2015
Full Text
View/download PDF

10. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis

Author

Faguer, Stanislas, primary, Vergez, François, additional, Peres, Michael, additional, Ferrandiz, Inès, additional, Casemayou, Audrey, additional, Belliere, Julie, additional, Cointault, Olivier, additional, Lavayssiere, Laurence, additional, Nogier, Marie-Béatrice, additional, Prevot, Grégoire, additional, Huart, Antoine, additional, Recher, Christian, additional, and Rostaing, Lionel, additional

Published
2014
Full Text
View/download PDF

12. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

Author

Cortes, Jorge E., primary, Goldberg, Stuart L., additional, Feldman, Eric J., additional, Rizzeri, David A., additional, Hogge, Donna E., additional, Larson, Melissa, additional, Pigneux, Arnaud, additional, Recher, Christian, additional, Schiller, Gary, additional, Warzocha, Krzysztof, additional, Kantarjian, Hagop, additional, Louie, Arthur C., additional, and Kolitz, Jonathan E., additional

Published
2014
Full Text
View/download PDF

13. Efficacy of lenalidomide in POEMS syndrome: A retrospective study of 20 patients

Author

Royer, Bruno, primary, Merlusca, Lavinia, additional, Abraham, Julie, additional, Musset, Lucile, additional, Haroche, Julien, additional, Choquet, Sylvain, additional, Leleu, Xavier, additional, Sebban, Catherine, additional, Decaux, Olivier, additional, Galicier, Lionel, additional, Roussel, Muriel, additional, Recher, Christian, additional, Banos, Anne, additional, Guichard, Isabelle, additional, Brisseau, Jean‐Marie, additional, Godmer, Pascal, additional, Hermine, Olivier, additional, Deplanque, Gaël, additional, Facon, Thierry, additional, Asli, Bouchra, additional, Leblond, Véronique, additional, fermand, Jean‐Paul, additional, Marolleau, Jean Pierre, additional, and Jaccard, Arnaud, additional

Published
2013
Full Text
View/download PDF

14. EVI1is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements

Author

Poppe, Bruce, primary, Dastugue, Nicole, additional, Vandesompele, Jo, additional, Cauwelier, Barbara, additional, De Smet, Betty, additional, Yigit, Nurten, additional, De Paepe, Anne, additional, Cervera, Jose, additional, Recher, Christian, additional, De Mas, Véronique, additional, Hagemeijer, Anne, additional, and Speleman, Frank, additional

Published
2005
Full Text
View/download PDF

18. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.

Author

Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poiré X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Adès L, and Fenaux P

Subjects
Adult, Aged, Anthracyclines administration & dosage, Belgium epidemiology, Chemoradiotherapy, Female, France epidemiology, Humans, Incidence, Leukemia, Promyelocytic, Acute diagnosis, Leukemia, Promyelocytic, Acute pathology, Male, Middle Aged, Mitoxantrone administration & dosage, Prospective Studies, Recurrence, Switzerland epidemiology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Promyelocytic, Acute epidemiology, Leukemia, Promyelocytic, Acute therapy
Abstract

Background: Reports of patients with secondary acute promyelocytic leukemia (APL) have increased in recent years, particularly for those who received treatment with mitoxantrone, and retrospective studies have suggested that their characteristics and outcomes were similar to those of patients with de novo APL., Methods: The authors investigated patients with de novo and secondary APL who were included in the ongoing APL-2006 trial. Patients with secondary APL who were included in that trial also were compared with a previous retrospective cohort of patients with secondary APL., Results: In the APL-2006 trial, 42 of 280 patients (15%) had secondary APL. Compared with the retrospective cohort, patients with secondary APL in the APL-2006 trial had a lower incidence of prior breast carcinoma (35.7% vs 57%; P = .03) and a higher incidence of prior prostate carcinoma (26.2% vs 4.7%; P < .001). Treatment of the primary tumor in the APL-2006 trial less frequently included combined radiochemotherapy (28.6% vs 47.2%; P = .044) and no mitoxantrone (0% vs 46.7%; P = .016) but more frequently included anthracyclines (53.3% vs 38.3%; P = .015). In the APL-2006 trial, patients who had secondary APL, compared with those who had de novo APL, were older (mean, 60.2 years vs 48.7 years, respectively; P < .0001) but had a similar complete response rate (97.6% vs 90.3%, respectively), cumulative incidence of relapse (0% vs 1.8%, respectively), and overall survival (92.3% vs 90.9%, respectively) at 18 months., Conclusions: Although the incidence of secondary APL appears to be stable over time, evolving strategies for the treatment of primary cancers have reduced its occurrence among breast cancer patients but have increased its incidence among patients with prostate cancer. The current results confirm prospectively that patients with secondary APL have characteristics and outcomes similar to those of patients with de novo APL., (© 2015 American Cancer Society.)

Published
2015
Full Text
View/download PDF

19. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

Author

Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC, and Kolitz JE

Subjects
Adult, Aged, Aminoglycosides administration & dosage, Amsacrine administration & dosage, Antibodies, Monoclonal, Humanized administration & dosage, Cladribine administration & dosage, Cytarabine administration & dosage, Daunorubicin administration & dosage, Disease-Free Survival, Etoposide administration & dosage, Female, Gemtuzumab, Humans, Injections, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute mortality, Liposomes, Male, Middle Aged, Mitoxantrone administration & dosage, Recurrence, Remission Induction, Risk Assessment, Treatment Outcome, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Acute drug therapy, Salvage Therapy methods
Abstract

Background: CPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy., Methods: This phase II study randomized 125 patients 2:1 to CPX-351 or investigators' choice of first salvage chemotherapy. Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history. Control salvage treatment was usually based on cytarabine and anthracycline, often with 1 or more additional agents. Survival at 1 year was the primary efficacy end point., Results: Patient characteristics were well balanced between the 2 study arms. Improvements in efficacy outcomes were observed following CPX-351, but did not meet prospectively defined statistical criteria for 1-year survival improvement in the overall population. Subset analyses of the EPI-defined poor-risk strata demonstrated higher response rates (39.3% vs 27.6%) and improvements in event-free survival (HR, 0.63; P = .08) and overall survival (HR, 0.55; P = .02). Also, 60-day mortality was lower in the CPX-351 study arm for poor-risk patients (16.1% vs 24.1%)., Conclusions: Taken together, the data suggest possible improved outcomes in CPX-351-treated first relapse AML patients with EPI-defined poor-risk disease., (© 2014 American Cancer Society.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results